



Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 8, 2022

PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14.

Krish Krishnan, Chairman and Chief Executive Officer, will deliver a presentation and host investor meetings on September 13.

A webcast of the presentation will be available [here](#) beginning at 2:30pm ET on Tuesday, September 13 and will be posted on the Investor section of the Company's [website](#).

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [Twitter](#).

CONTACT:

Investors and Media:

Meg Dodge
Krystal Biotech
mdodge@krystalbio.com



Source: Krystal Biotech, Inc.